Pawel Osmulski and Devalingam Mahalingam contributed equally to this work.
Nanomechanical biomarkers of single circulating tumor cells for detection of castration resistant prostate cancer
Article first published online: 25 JUL 2014
© 2014 Wiley Periodicals, Inc.
Volume 74, Issue 13, pages 1297–1307, September 2014
How to Cite
Osmulski, P., Mahalingam, D., Gaczynska, M. E., Liu, J., Huang, S., Horning, A. M., Wang, C.-M., Thompson, I. M., Huang, T. H.-M. and Chen, C.-L. (2014), Nanomechanical biomarkers of single circulating tumor cells for detection of castration resistant prostate cancer. Prostate, 74: 1297–1307. doi: 10.1002/pros.22846
- Issue published online: 11 AUG 2014
- Article first published online: 25 JUL 2014
- Manuscript Accepted: 4 JUN 2014
- Manuscript Received: 21 MAY 2014
- Integrative Cancer Biology Program. Grant Number: U54CA113001
- Early Detection Research Network. Grant Number: U01CA086402
- Cancer Center Support Grant. Grant Number: P30CA054174
- National Institutes of Health
- University of Texas STARS Award
- Cancer Therapy and Research Center Fund
- Voelcker Fund
- GMaP Region 4 NCI Early Career Cancer Health Disparities Researcher Scholarship
- biophysical biomarkers;
- single-cell analysis;
Emerging evidence shows that nanomechanical phenotypes of circulating tumor cells (CTC) could become potential biomarkers for metastatic castration resistant prostate cancer (mCRPC).
To determine the nanomechanical phenotypes of CTCs we applied atomic force microscopy (AFM) employing the PeakForce quantitative nanomechanical (QNM) imaging. We assessed biophysical parameters (elasticity, deformation, and adhesion) of 130 CTCs isolated from blood samples from five castration sensitive (CS) and 12 castration resistant prostate cancer (CRPCa) patients.
We found that CTCs from CRPCa patients are three times softer, three times more deformable, and seven times more adhesive than counterparts from CSPCa patients. Both nonsupervised hierarchical clustering and principle component analysis show that three combined nanomechanical parameters could constitute a valuable set to distinguish between CSPCa and CRPCa.
Our study indicates that nanomechanical phenotypes of CTCs may serve as novel and effective biomarkers for mCRPC. Prostate 74: 1297–1307, 2014. © 2014 Wiley Periodicals, Inc.